Pharmaceutical Approval Update
Other
public-domain-us
AI-generated summary
The pharmaceutical approval update lists Ivosidenib for acute myeloid leukemia, elagolix for endometriosis, and mogamulizumab-kpkc for mycosis fungoides or Sézary syndrome.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Ivosidenib (Tibsovo) for acute myeloid leukemia; elagolix (Orilissa) for endometriosis; and mogamulizumab-kpkc (Poteligeo) for mycosis fungoides or Sézary syndrome.
My notes (saved in your browser only)
Condition tags
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-11-11T06:12:07.612938+00:00
- pubmed
- last seen: 2026-10-08T21:23:08.188623+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine